Precision medicine: do not neglect the hurdles
Journal Title: Advances in Precision Medicine - Year 2016, Vol 1, Issue 2
Abstract
Tremendous expectations have been connected with precision medicine in the past years. Beside the advantages that this type of therapy offers we should be aware of its challenges too. In this issue we will highlight on specific challenges that the pharmacological industry is opposed with when developing new targeted therapies. In addition, we will discuss issues with the reproducibility of published scientific data.
Authors and Affiliations
Lilla Landeck, Patricia Carrigan and Khusru Asadullah
Keywords
Related Articles
- EP ID EP679268
- DOI -
- Views 181
- Downloads 0
Reproducibility of preclinical data: one man's poison is another man's meat
Limited reproducibility of preclinical data is increasingly discussed in the literature. Failure of drug development programs due to lack of clinical efficacy is also of growing concern. The two phenomena may share an im...
Prioritization of COPD protein biomarkers, based on a systematic study of the literature
Chronic Obstructive Pulmonary Disease (COPD) is a chronic lung disease mostly due to smoking and until now diagnosed by spirometry (post bronchodilator FEV1/FVC <70%). However, in spite of the usefulness of FEV1 as diagn...
The research data reproducibility problem solicits a 21st century solution
Reproducibility is a hallmark of scientific efforts. Estimates indicate that lack of reproducibility of data ranges from 50% to 90% among published research reports. The inability to reproduce major findings of published...
A classifier driven approach to find biomarkers for affective disorders from transcription profiles in blood
Gene expression profiles in blood are increasingly being used to identify biomarkers for different affective disorders. We have selected a set of 29 genes to generate expression profiles for healthy control subjects as w...
Genomics Vault: A framework for precision medicine data management
A mixture of fumaric acid esters (FAEs) is approved for the oral therapy of psoriasis. However, for a long time the active ingredient of this mixture was unknown. We reviewed the in vitro data available for the different...